News from sillajen, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 16, 2019, 13:31 ET SillaJen Defending Position Relating to Recent Sale of Stock by Employee

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Aug 02, 2019, 09:00 ET SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Jun 06, 2019, 09:00 ET SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Sep 04, 2018, 09:00 ET SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Jun 20, 2018, 09:00 ET SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Feb 23, 2018, 09:00 ET SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Jan 29, 2018, 09:00 ET SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Jan 22, 2018, 04:33 ET SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Aug 16, 2017, 19:30 ET SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Jul 21, 2017, 00:00 ET SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

Apr 24, 2017, 11:45 ET SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, ...

May 31, 2016, 09:00 ET SillaJen Announces Poster Presentation at ASCO Annual Meeting

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today...

May 16, 2016, 09:00 ET SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL ...

Mar 29, 2016, 09:00 ET SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has...

Jan 05, 2016, 06:00 ET SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has...

Jun 29, 2015, 07:00 ET SillaJen Publishes Clinical Data Demonstrating Safe Administration of Multiple Intravenous Doses of Oncolytic Virus in Patients with Metastatic Colorectal Cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today...

Apr 20, 2015, 03:00 ET SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today...

Apr 16, 2015, 12:00 ET SillaJen Announces Agreement with the FDA for a Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has...

Jul 10, 2014, 07:00 ET SillaJen Inc. Lead Product Pexa-Vec Featured in "Nature Reviews Cancer" Article Summarizing the Potential of Oncolytic Immunotherapy

SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer,...

Jun 20, 2014, 07:00 ET SillaJen Biotherapeutics To Present at the BIO Business Forum

SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer,...

Jun 19, 2014, 04:02 ET SillaJen Biotherapeutics Announces Completion of Name Change Following Acquisition of Jennerex

SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer,...

Mar 17, 2014, 10:37 ET SillaJen Announces Completion of Jennerex, Inc. Acquisition

SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer,...